NCT07477756Completed
A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients
Real-World Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients Receiving Lutetium-177 Vipivotide Tetraxetan
Source: ClinicalTrials.gov · Last updated 19 Mar 2026
Brief summary (registry, in English)
The aim of this study was to assess the characteristics, treatment patterns, and clinical outcomes among metastatic castration-resistant prostate cancer (mCRPC) patients in the United States (US) who were treated with lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617) in the real-world setting.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1247 (actual)
- First submitted
- 12 Mar 2026
- Start date
- 4 Sept 2024
- Primary completion date
- 14 Mar 2025
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Prostate cancer
- NCT number
- NCT07477756
What you commit to
- Study type: Observational
- Participants enrolled: 1247
- From 4 Sept 2024 to the primary completion date, 14 Mar 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Evidence of 177Lu-PSMA-617 use on or after March 23, 2022
- Date of initiation of 177Lu-PSMA-617 available in the data
- Age ≥18 years at index
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Coordinator of this site? Confirm its status | East Hanover | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.